Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Camilla Gigg"'
Autor:
Georg Schett, Johannes Knitza, Martin Krusche, Johanna Mucke, Arnd Kleyer, Nicolas Vuillerme, Felix Muehlensiepen, Gerlinde Bendzuck, Gerhard Krönke, Sebastian Boeltz, David Simon, Joshua Zarbl, Ekaterina Eimer, Camilla Gigg, Marianne Korinth, Corinna Elling-Audersch
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objectives To evaluate the feasibility, accuracy, usability and acceptability of two upper arm self-sampling devices for measurement of autoantibodies and C reactive protein (CRP) levels in patients with immune-mediated rheumatic diseases (IMRDs).Met
Externí odkaz:
https://doaj.org/article/0e2804d053bf4759a6c017329851d78b
Autor:
Joshua Zarbl, Ekaterina Eimer, Camilla Gigg, Gerlinde Bendzuck, Marianne Korinth, Corinna Elling-Audersch, Arnd Kleyer, David Simon, Sebastian Boeltz, Martin Krusche, Johanna Mucke, Felix Muehlensiepen, Nicolas Vuillerme, Gerhard Krönke, Georg Schett, Johannes Knitza
ObjectivesTo evaluate the feasibility, accuracy, usability and acceptability of two upper arm self-sampling devices for measurement of autoantibodies and C reactive protein (CRP) levels in patients with immune-mediated rheumatic diseases (IMRDs).Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e19216f118356bcd402a36abbbfdbb4
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/20252
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/20252
Autor:
Hannah Karlsson, Emma Svensson, Camilla Gigg, Malin Jarvius, Ulla Olsson-Strömberg, Barbara Savoldo, Gianpietro Dotti, Angelica Loskog
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144787 (2015)
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although mainly second generation (2G) CARs carrying CD28 or 4-1BB have been investigated in patients, preclinical studies suggest that third generation (3G)
Externí odkaz:
https://doaj.org/article/23e186a8ec914e45b4c3f9cd70cc82b1
Autor:
Emma Svensson, Barbara Savoldo, Malin Jarvius, Hannah Karlsson, Angelica Loskog, Ulla Olsson-Strömberg, Camilla Gigg, Gianpietro Dotti
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 12, p e0144787 (2015)
PLoS ONE, Vol 10, Iss 12, p e0144787 (2015)
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although mainly second generation (2G) CARs carrying CD28 or 4-1BB have been investigated in patients, preclinical studies suggest that third generation (3G)